Oslo, 12 November -- On 3 September, ContextVision AB ("ContextVision" or the
"Company") announced a share buy-back programme of up to NOK 10,000,000, with
a maximum of 4,000,000 shares, in the period from 5 September 2025 to 5 March
2026.
DNB Carnegie, acting under the mandate from ContextVision, has carried out the
following transactions under the buy-back programme:
+---------------------+------------------+---------------+-------------------+
| Date | Aggregated daily | Weighted | Total daily |
| | volume (number | average share | transaction value |
| | of shares) | price per day | (NOK) |
| | | (NOK) | |
+---------------------+------------------+---------------+-------------------+
| 2025-11-04 | 1 322 | 4,3084 | 5 738,78 |
+---------------------+------------------+---------------+-------------------+
| 2025-11-05 | 6 795 | 4,3630 | 29 646,58 |
+---------------------+------------------+---------------+-------------------+
| 2025-11-06 | 9 636 | 3,9306 | 37 875,26 |
+---------------------+------------------+---------------+-------------------+
| 2025-11-07 | 3 077 | 3,7925 | 11 669,52 |
+---------------------+------------------+---------------+-------------------+
| 2025-11-10 | 5 453 | 3,7000 | 20 176,10 |
+---------------------+------------------+---------------+-------------------+
| 2025-11-11 | 2 533 | 3,7414 | 9 476,96 |
+---------------------+------------------+---------------+-------------------+
| 2025-11-12 | 8 297 | 3,7642 | 31 231,56 |
+---------------------+------------------+---------------+-------------------+
| Previously | 421 548 | 4,5076 | 1 905 419,64 |
| disclosed buy-buys | | | |
| under the programme | | | |
| (accumulated) | | | |
+---------------------+------------------+---------------+-------------------+
| Accumulated under | 458 661 | 4,4269 | 2 030 446,38 |
| the buy-back | | | |
| programme | | | |
+---------------------+------------------+---------------+-------------------+
Following the completion of the above transactions, ContextVision owns a total
of 2 258 371 of own shares, corresponding to 2,92% of ContextVision's share
capital.
An overview of all transactions made under the buy-back programme that have
been carried out during the abovementioned time period is attached to this
report and available at www.newsweb.no (http://www.newsweb.no/).
This is information that ContextVision is obliged to make public pursuant to
the EU Market Abuse Regulation and that is subject to the disclosure
requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.
This stock exchange announcement was published by Richard Hallström, CFO, on
the time and date provided.
For further information, please contact:
Richard Hallström, CFO
Email: richard.hallstrom@contextvision.com
About ContextVision AB: ContextVision is a medical technology software company
specialized in image analysis and artificial intelligence. As the global
market leader within image enhancement, we are a trusted partner to leading
manufacturers of ultrasound, X-ray and MRI equipment around the world. Our
expertise is to develop powerful software products, based on proprietary
technology and artificial intelligence for image-based applications. Our
cutting-edge technology helps clinicians accurately interpret medical images,
a crucial foundation for better diagnosis and treatment. The company,
established in 1983, is based in Sweden with local representation in the U.S.,
Japan, China and Korea. ContextVision is listed on the Oslo Stock Exchange
under the ticker CONTX.
This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 17. The information was submitted for publication at
2025-11-12 17:11 CET.